CSL announces rise in full year net profit

Major strategic initiatives, including demerger, to transform CSL

MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit (NPATA) was US$3.3 billion, up 14% on a constant currency basis.

Dr. Paul McKenzie, CSL's Chief Executive Officer and Managing Director said, "I am pleased to report another on-target result for the 2025 financial year, led by CSL Behring and continued strong demand for our life-saving plasma therapies.

"CSL Seqirus continued to show the resilience of its differentiated portfolio and platforms by generating growth in a challenging environment. CSL Vifor grew strongly, underpinned by our resilient iron business and pleasing momentum across the nephrology portfolio," Dr. McKenzie said. 

Today, the company announced a suite of strategic transformation initiatives designed to ensure continued growth and resilience in a complex operating environment. 

"Our business has grown this year despite an unprecedented level of challenge and volatility in our external operating environment. Today we are announcing transformational initiatives to reshape and simplify the business, enhance clinical and commercial execution and provide a platform for CSL to focus on our core strengths," Dr. McKenzie said.

"These changes are designed to focus our organisation on three Ps: Pipeline, Productivity and People. They will make us match-fit and instil a lean and efficient mindset, reduce complexity and simplify our operating model."

A summary of these initiatives is outlined below: 

Driving Growth, Simplification and Shareholder Returns 

Research &Development 

OperatingModel 

PlasmaNetwork 

CSL remains steadfast in its commitment to innovation and will drive specific changes that increase the speed of translational research into the clinical setting, while continuing to offer life cycle management expansion to our portfolio. 

 

CSL will reduce the proportion of fixed cost in overall spend, and implement initiatives to increase pipeline productivity, including consolidation of R&D ...